FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2023/02/049929 [Registered on: 21/02/2023] Trial Registered Prospectively
Last Modified On: 21/02/2023
Post Graduate Thesis  No 
Type of Trial  PMS 
Type of Study   Ayurveda
Nutraceutical 
Study Design  Single Arm Study 
Public Title of Study   To check the effect of Migraine -XS tablet in patients having Migraine 
Scientific Title of Study   An open label single arm clinical study to evaluate the efficacy of Migraine-XS tablet in Migraine 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
MGCTS/20/114 version1.0 dated 27August 2022  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Rakhi Mehra  
Designation  Principal Investigator 
Affiliation  Shree Ram Hospital  
Address  Dept of General Medicine, Room-8, Ground Floor, Shree Ram Hospital, NH-58, Delhi - Haridwar Highway, Partapur Bypass Rd, Meerut

Meerut
UTTAR PRADESH
250103
India 
Phone  7015579562  
Fax    
Email  raakhimehra49@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Puneet Mittal  
Designation  Clinical Research Consultant  
Affiliation  Mittal Global Clinical Trial Services  
Address  Dept of Clinical Research, First Floor, MGCTS Building, Mansarovar Ind Estate, Panchli Khurd, Baghpat Road

Meerut
UTTAR PRADESH
250002
India 
Phone  8937045757   
Fax    
Email  puneetmittal@mgcts.org  
 
Details of Contact Person
Public Query
 
Name  Puneet Mittal  
Designation  Clinical Research Consultant  
Affiliation  Mittal Global Clinical Trial Services  
Address  Dept of Clinical Research, First Floor, MGCTS Building, Mansarovar Ind Estate, Panchli Khurd, Baghpat Road

Meerut
UTTAR PRADESH
250002
India 
Phone  8937045757   
Fax    
Email  puneetmittal@mgcts.org  
 
Source of Monetary or Material Support  
Mittal Ayurved Sansthan, Sant Vihar, T. P. Nagar, Meerut 
 
Primary Sponsor  
Name  M Global Nutraceuticals 
Address  A Mittal Ayurved Sansthan Company, 121-B, Mansarovar Industrial Estate, Panchli Khurd, Baghpat Road, Meerut, India 
Type of Sponsor  Pharmaceutical industry-Indian 
 
Details of Secondary Sponsor  
Name  Address 
Not Applicable  Not Applicable 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Rakhi Mehra  Shree Ram Hospital   Dept of General Medecine, Room-8, Ground Floor, Shree Ram Hospital, NH-58, Delhi-haridwar highway, Partapur Byepass rd, Meerut
Meerut
UTTAR PRADESH 
7906672912

raakhimehra49@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
SRAMCH Institutional Ethics Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition:G439||Migraine, unspecified. Ayurveda Condition: ARDHAVABEDAKAH,  
 
Intervention / Comparator Agent  
snoIntervention/ComparatorTypeDrug-TypeProcedure NameDetails
1Intervention ArmDrugOther than Classical(1) Medicine Name: Migraine XS Tablets, Reference: NA, Route: Oral, Dosage Form: Gutika/Vati/Ghana Vati/Tablets, Dose: 1000(mg), Frequency: bd, Bhaishajya Kal: Adhobhakta, Duration: 1 Months, anupAna/sahapAna: No, Additional Information: -
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  65.00 Year(s)
Gender  Both 
Details  1.Subjects of either sex
2.Age 18-65 years (both inclusive)
3.People who have severe pain at half portion of their head.
4.If female of childbearing potential, must be willing to practice an acceptable form of birth control for the duration of the study.
5.Are able to give written informed consent in a manner approved by the Institutional Ethics Committee and comply with the requirements of the study.
6.Are willing to avoid participation in any other interventional clinical trial for the duration of this study.
7.Are willing to refrain from using any lotions, gel, balm, other than those issued as part of the study, on the treatment areas during the treatment period.
 
 
ExclusionCriteria 
Details  1.Are pregnant, breast-feeding, or planning to become pregnant during the study.
2.Cluster headache patients(its different from migraine)
3.Have participated in any interventional clinical trial in the previous 30 days.
4.Have a known sensitivity to any of the constituents of the test products .
5.Have a history of alcohol or illegal drug/substance abuse, or suspected alcohol or illegal drug/substance abuse in the past 2 years.
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Case Record Numbers 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Change in the Subject Global Assessment  day 0 and Day 30 
 
Secondary Outcome  
Outcome  TimePoints 
change in pain (0-4)  day 0 and Day 30 
Change in Migraine Severity scores (MIGSEV)  day 0 and Day 30 
Change in Migraine Disability Assessment(MIDAS) score  day 0 and Day 30 
 
Target Sample Size   Total Sample Size="37"
Sample Size from India="37" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Post Marketing Surveillance 
Date of First Enrollment (India)   25/02/2023 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details   Nil 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Migraine is a spectrum disease, usually manifesting as an episodic or chronic primary headache disorder, characterized by attacks that can last from a few hours to up to three days. It is two to three times more prevalent among women than men, and women experience higher levels of pain, longer lasting attacks, and greater disability than men. For much of the twentieth century, migraine’s causes were considered to be vascular, and the pain a result of dilation of the cranial blood vessels. Since the 1970s, the emphasis has shifted, and it is now defined as a disorder involving nerve pathways and chemicals in the brain, to which people are often genetically predisposed. While migraine is still understood to affect the neurovascular system, it seems likely that the headache pain comes from neurogenic inflammation, rather than vasodilation. This is a problem of brain function, rather than structure. As the website for the National Migraine Centre in London explains, “if the brain is a computer, migraine is a software not a hardware problem.” Nevertheless, a huge amount remains unknown, including the role of the hypothalamus (the part of the brain that controls the endocrine system and has a role in the menstrual cycle, pain modulation, and governance of the body’s circadian rhythms), the cause of premonitory symptoms, the extent to which antimigraine drugs can access the brain, and the role of the blood-brain barrier.


 
Close